Overall, the combination of sertraline and erlotinib offers a potential therapeutic strategy for NSCLC and highlights the role of AMPK/mTOR/S6K in the maintenance of EGFR mutant cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.